This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Krug, L. M. Articles by Livingston, P. O. Search for Related Content PubMed PubMed Citation Articles by Krug, L. M. Articles by Livingston, P. O.

Vaccination of Small Cell Lung Cancer Patients with Polysialic Acid or N-Propionylated Polysialic Acid Conjugated to Keyhole Limpet Hemocyanin

¹ Thoracic Oncology Service and ² Laboratory of Tumor Vaccinology, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York, and ³ Institute of Biological Sciences, National Research Council of Canada, Ottawa, Ontario, Canada

Purpose: Long chain polysialic acid (polySA) is a side chain on embryonal neural cell adhesion molecules that, in the adult, is largely restricted to small cell lung cancer (SCLC). Long chains of polySA are also expressed on group B meningococcus. In this clinical trial, we aimed to elicit an immune response against polysialic acid to target clinically inapparent residual disease in patients with SCLC who had successfully completed initial therapy.

Experimental Design: Patients were vaccinated with either 30 µg unmodified polySA or N-propionylated-polySA (NP-polySA), conjugated to keyhole limpet hemocyanin (KLH) and mixed with 100 µg of immunological adjuvant QS-21 at weeks 1, 2, 3, 4, 8, and 16.

Results: Of the 5 evaluable patients vaccinated with unmodified polySA, only 1 mounted an IgM antibody response to polySA. On the other hand, all 6 of the patients vaccinated with NP-polySA produced IgM antibodies to NP-polySA and these cross-reacted with unmodified polySA in all but 1 case. IgG antibodies to NP-polySA were observed in 5 of the patients, but these did not cross-react with polySA. The presence of IgM antibodies reactive with SCLC cell lines was confirmed in this group by flow cytometry. Complement-dependent lysis of tumor cells could not be demonstrated. However, postimmunization sera induced significant bactericidal activity against group B meningococcus when combined with rabbit complement.

Conclusions: Vaccination with NP-polySA-KLH, but not polySA-KLH, resulted in a consistent high titer antibody response. We are now conducting a de-escalation dosing study with NP-polySA-KLH to better assess the immunogenicity, toxicities, and optimal dose of this vaccine. We plan to incorporate this vaccine as a component of a polyvalent vaccine with GM2, fucosylated GM1, and Globo H to target SCLC.

This article has been cited by other articles:

				H. Geyer, M. Wuhrer, A. Resemann, and R. Geyer Identification and Characterization of Keyhole Limpet Hemocyanin N-Glycans Mediating Cross-reactivity with Schistosoma mansoni J. Biol. Chem., December 9, 2005; 280(49): 40731 - 40748. [Abstract] [Full Text] [PDF]

				L. E. Raez, S. Fein, and E. R. Podack Lung Cancer Immunotherapy Clin. Med. Res., November 1, 2005; 3(4): 221 - 228. [Abstract] [Full Text] [PDF]

				G. Ragupathi, N. X. Liu, C. Musselli, S. Powell, K. Lloyd, and P. O. Livingston Antibodies against Tumor Cell Glycolipids and Proteins, but Not Mucins, Mediate Complement-Dependent Cytotoxicity J. Immunol., May 1, 2005; 174(9): 5706 - 5712. [Abstract] [Full Text] [PDF]

				L. M. Krug, G. Ragupathi, C. Hood, M. G. Kris, V. A. Miller, J. R. Allen, S. J. Keding, S. J. Danishefsky, J. Gomez, L. Tyson, et al. Vaccination of Patients with Small-Cell Lung Cancer with Synthetic Fucosyl GM-1 Conjugated to Keyhole Limpet Hemocyanin Clin. Cancer Res., September 15, 2004; 10(18): 6094 - 6100. [Abstract] [Full Text] [PDF]